Cost-effectiveness of integrated prevention for late-life depressive symptoms: Real-world findings from a large-scale pragmatic trial ("JoyAge").

J Affect DisordMay 20, 2026 (epub)
Clinical ResearchPsychiatryGeriatrics

Shiyu Lu, Tianyin Liu, Dara Kiu Yi Leung et al.

✦ AI-curated · Sources linked

In 30 seconds

This pragmatic non-randomised controlled trial evaluated the cost-effectiveness of the JoyAge integrated prevention program for late-life depression in a sample of 3,416 participants. JoyAge demonstrated an incremental effectiveness of 31.86 depression-free days (DFDs) and 0.01 quality-adjusted life years (QALYs) at an incremental cost of US$251, indicating strong cost-effectiveness compared to usual care.

Key findings

  • JoyAge resulted in 31.86 additional depression-free days (DFDs) at an incremental cost of US$251.
  • The incremental cost-effectiveness ratio was US$9 per DFD and US$20,063 per QALY.
  • JoyAge has a 95% likelihood of being cost-effective at US$24 per DFD and 99.9% for QALYs using WHO thresholds.
  • Selective prevention was more effective in gaining DFDs and QALYs compared to usual care.

Why it matters

Understanding the cost-effectiveness of integrated prevention programs like JoyAge is crucial for addressing late-life depression, especially in resource-limited settings. Effective interventions can improve quality of life and reduce healthcare costs.

Source

PubMed · PMID 42167691

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.